alpha-aminopyridine has been researched along with lde225 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beroukhim, R; Buonamici, S; Chung, J; Dabral, SK; Dorsch, M; Filbin, MG; Franchetti, Y; Kelleher, JF; Kung, AL; Ligon, KL; Pak, E; Pazyra-Murphy, MF; Ramkissoon, S; Redjal, N; Segal, RA; Shulman, DS; Sun, Y; Tabak, B; Theisen, MA; Wang, Q; Zhao, J | 1 |
Brotherton, R; Chang, ALS; Moffat, A; Pague, A; Tran, DC; Zhu, GA | 1 |
2 other study(ies) available for alpha-aminopyridine and lde225
Article | Year |
---|---|
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Topics: Aminopyridines; Animals; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Glioblastoma; Hedgehog Proteins; Humans; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Ribosomal Protein S6 Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carcinoma, Basal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Prospective Studies; Pyridines; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2018 |